Zenas BioPharma, Inc. (ZBIO) stock
Close on Nov 12, 2026Market cap $1.80BP/E –Yield –
Zenas BioPharma, Inc. grew revenue 100.0% to $10.00M over fiscal 2025. Free cash flow was -$242.83M. At the latest close the market valued the company at $1.80B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $1.80B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 8.49
- Dividend yield
- –
- Free cash flow yield
- -13.48%
Fundamentals
- Revenue
- $10.00M
- Net income
- -$541.81M
- EPS, diluted
- -$9.41
- Free cash flow
- -$242.83M
- Book value per share
- $3.21
- Diluted shares
- 66M
Trading
- Next earnings
- Mar 15, 2027 (estimated, before the open)
- Previous close
- $28.70
- Open
- $28.18
- Day's range
- $27.42 – $28.75
- Volume
- 752,030
- Average volume (20 days)
- 520,112
- Index membership
- Russell 2000 (since Dec 2024), Russell 3000 (since Nov 2024)
- Beta (5 years)
- 0.39
- 52-week range
- $13.50 – $44.60
- RSI (14 days)
- 48.3
- Volatility (1 year)
- 95.1%
- Relative volume
- 1.12×
- WACC
- 7.2%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZBIO | S&P 500 | Difference | ZBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.7% | -2.7% | +7.4 pts | ||
| 3 months | -11.7% | -1.7% | −9.9 pts | ||
| Year to date | -23.9% | +11.9% | −35.8 pts | ||
| 1 year | -22.8% | +12.0% | −34.8 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zenas BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Zenas BioPharma
Pharmaceutical Preparations
Zenas is a clinical-stage biopharmaceutical company that develops therapies for patients with autoimmune and inflammatory diseases. It acquires and develops product candidates directed at immune targets, without having any approved commercial products or sales revenue. Its lead candidate, obexelimab, is a monoclonal antibody that inhibits B-cell activity without cell destruction for conditions including immunoglobulin G4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus. The company also advances orelabrutinib for progressive forms of multiple sclerosis, along with early-stage candidates ZB021 and ZB022. Its end users are patients suffering from autoimmune conditions.
Company profile, executives and historyZenas BioPharma stock: common questions
What is Zenas BioPharma's stock price?
ZBIO closed at $27.64 on Nov 12, 2026, down 3.69% on the day. Over the past 52 weeks it traded between $13.50 and $44.60.
What is Zenas BioPharma's market cap?
Zenas BioPharma was worth $1.80B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ZBIO's P/E ratio?
Zenas BioPharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$9.41), so it has no meaningful P/E ratio.
How much revenue does Zenas BioPharma make?
Zenas BioPharma reported revenue of $10.00M for fiscal 2025, up 100.0% from a year earlier.
Does Zenas BioPharma pay a dividend?
No. Zenas BioPharma has not paid a cash dividend over the last twelve months.
When does Zenas BioPharma report earnings next?
Zenas BioPharma is expected to report Q4 FY2026 results on Mar 15, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ZBIO stock performed over the past year?
Including dividends, ZBIO returned -22.8% over the past year, against +12.0% for the S&P 500.
How many ZBIO shares are sold short?
11M shares were sold short at the latest FINRA report, 27.27% of the float, or 24.1 days of average trading volume.
Who are Zenas BioPharma's competitors?
Companies most similar to Zenas BioPharma by business, industry and size include ALMS, ACRS, HCWB, XENE, EVMN.
See a number that looks wrong?